Psilocybin Therapy Cuts Suicidal Thoughts in 70% of Patients

For people living with chronic suicidal thoughts that don't respond to traditional treatments, a new study offers something psychiatry hasn't been able to deliver: rapid relief that lasts.

Researchers at Sheppard Pratt in Baltimore gave 20 adults with treatment-resistant depression and chronic suicidal ideation a single 25-mg dose of psilocybin alongside structured therapy sessions. Within one week, participants showed significant reductions in suicidal thoughts that continued for the entire 12-week study period.

The results surprised even the researchers. By week 12, 70% of participants reported minimal or no suicidal thoughts at all.

All 20 participants had tried at least two antidepressant medications that failed to help. They received psychological preparation before the psilocybin dose, careful supervision during the experience, and follow-up integration sessions afterward.

Depression symptoms also dropped significantly across every assessment point. No serious adverse events occurred during the trial, which operated under FDA authorization and institutional review board approval.

"Chronic suicidality remains one of the most difficult symptoms to treat in psychiatry, particularly for patients who have not responded to conventional therapies," said Dr. Scott Aaronson, chief science officer at Sheppard Pratt and lead researcher on the study. The findings appeared in the Journal of Clinical Psychiatry in June 2026.

Why This Inspires

This study breaks new ground by focusing on a group often left behind. People with active suicidal thoughts are typically excluded from psychedelic clinical trials, despite desperately needing new treatment options.

Dr. Andrew van der Vaart, the study's first author, emphasized this point. These participants had nowhere else to turn, yet the carefully structured clinical setting provided both safety and hope.

The speed matters too. While traditional antidepressants can take weeks to show effects (if they work at all), psilocybin therapy produced measurable improvements within seven days that didn't fade over time.

Larger randomized controlled trials will need to confirm these findings and evaluate long-term safety. But for a field that has struggled to help people with chronic suicidal ideation, this represents genuine progress toward understanding whether psychedelic-assisted therapies can offer another path forward when everything else has failed.

For families watching loved ones suffer without relief, that possibility alone feels like breakthrough news.